Merilog 100units/mL is supplied as both a 10mL multi-dose vial as well as a 3mL single-patient-use prefilled pen; the prefilled pen dials in 1-unit increments. The rapid-acting insulin should be ...

The FDA has approved ViiV/Johnson & Johnson’s Cabenuva long-acting HIV treatment in a long-awaited decision that can free patients from a daily dosing regimen to an injection taken every month.

The drug is a long-acting and potent serotonin 5-HT1A receptor ... AI in drug discovery is evolving fast - in September last year another R&D house, Deep Genomics, said it had used artificial ...

Merilog is a rapid-acting human insulin analog and the first rapid-acting insulin biosimilar product approved by the Food and Drug Administration. HealthDay News — The U.S. Food and Drug ...

a DB = double-blind, DM = diabetes mellitus, HbA 1c = glycosylated hemoglobin, MC = multicenter, NPH = isophane insulin human, NR = not recorded, OL = open-label, PG = parallel-group, R = randomized.

The rapid-acting insulin should be administered subcutaneously within 5-10 minutes before a meal into the abdominal area, thigh, buttocks, or upper arm. The dosage is based on the patient’s ...

Feb. 20, 2025 -- The FDA has approved a new fast-acting insulin biosimilar to help manage blood sugar in people with diabetes, including children and adults. The product, called Merilog ...

as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus. Merilog is a rapid-acting human insulin analog and the first rapid-acting insulin biosimilar ...

FDA Approves First Rapid-Acting Insulin Biosimilar for Patients With Diabetes By Stephanie Brown HealthDay Reporter WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- The U.S. Food and Drug ...

Sanofi-Aventis' Merilog is the first FDA-approved rapid-acting insulin biosimilar. On Feb. 14, the agency approved the drug, a biosimilar to Novolog, for glycemic control improvement in adult and ...